PMID- 29883249
OWN - NLM
STAT- MEDLINE
DCOM- 20190617
LR  - 20211204
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 14
IP  - 11
DP  - 2018
TI  - Rabies post-exposure prophylaxis for a male with severe Henoch Schonlein purpura 
      following rabies vaccination.
PG  - 2666-2668
LID - 10.1080/21645515.2018.1486354 [doi]
AB  - Henoch Schonlein purpura (HSP) following vaccine administration has been 
      described in case reports and in a small number of observational studies. We 
      herein reported a case of HSP occurring in an otherwise healthy 37-year-old male 
      after immunization with lyophilized purified vero cell rabies vaccine (PVRV). 
      After the anti-allergy therapy with hormone, the purpuric lesions gradually 
      disappeared. After evaluating, another PVRV with different dose (0.5 ml), 
      strains, excipient and without residues was chosen for the new anti-rabies 
      immunization program, and the patient has had no recurrence of allergic symptoms. 
      Although significant lower than the levels of normal 20-50 year population at day 
      21, the neutralizing antibody (RVNA) titers of this boy showed adequate 
      protective antibody (3.23 vs 7.15 IU/ml). This case report emphasizes 
      the importance that clinicians should be aware of HSP as a potential adverse 
      event associated with PVRV vaccination. And adverse events (AEs) after 
      immunization should be carefully treated, changing immunization program in time 
      is necessary. While enrolling a new anti-rabies immunization program, the 
      properties of different rabies vaccines taking with special emphasis on strains, 
      excipient and residues is imperative before vaccination so that an appropriate 
      immune program can be managed to be initiated.
FAU - Zhu, Zheng-Gang
AU  - Zhu ZG
AD  - a Department of Immunization , Wuhan Center for Disease Prevention and Control , 
      Wuhan , China.
FAU - Zheng, Yi
AU  - Zheng Y
AUID- ORCID: 0000-0002-4953-6004
AD  - b Department of Leprosy , Wuhan Institute of Dermatology and Venereology , Wuhan 
      , China.
FAU - Lu, Sha
AU  - Lu S
AD  - a Department of Immunization , Wuhan Center for Disease Prevention and Control , 
      Wuhan , China.
FAU - Hu, Quan
AU  - Hu Q
AD  - b Department of Leprosy , Wuhan Institute of Dermatology and Venereology , Wuhan 
      , China.
FAU - Fang, Yuan
AU  - Fang Y
AD  - c Department of Neurology, Union Hospital, Tongji Medical College , Huazhong 
      University of Science and Technology , Wuhan , China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20180629
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Rabies Vaccines)
SB  - IM
MH  - Adult
MH  - Animals
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Antibodies, Viral/blood
MH  - Bites and Stings/virology
MH  - Dogs
MH  - Humans
MH  - IgA Vasculitis/blood/drug therapy/*etiology
MH  - Male
MH  - *Post-Exposure Prophylaxis
MH  - Rabies/*prevention & control/transmission
MH  - Rabies Vaccines/administration & dosage/*adverse effects
MH  - Rabies virus/immunology
PMC - PMC6314408
OTO - NOTNLM
OT  - Henoch Schonlein purpura (HSP)
OT  - allergic reaction
OT  - neutralizing antibody (RVNA) titer
OT  - purified vero cell rabies vaccine (PVRV)
OT  - rabies virus neutralizing antibody (RVNA)
EDAT- 2018/06/09 06:00
MHDA- 2019/06/18 06:00
PMCR- 2019/06/29
CRDT- 2018/06/09 06:00
PHST- 2018/06/09 06:00 [pubmed]
PHST- 2019/06/18 06:00 [medline]
PHST- 2018/06/09 06:00 [entrez]
PHST- 2019/06/29 00:00 [pmc-release]
AID - 1486354 [pii]
AID - 10.1080/21645515.2018.1486354 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2018;14(11):2666-2668. doi: 10.1080/21645515.2018.1486354. 
      Epub 2018 Jun 29.